Table 1 Basic data
Variables | Data of all patients |
|---|---|
n | 387 |
Gender(male/female) | 204/183 |
Age (years old) | 45.9 ± 16.3 |
Other autoimmune disorders (no/yes) | 345/42 |
Preoperative history of myasthenic crisis (no/yes) | 380/7 |
Preoperative course (< 12 months/ ≥ 12 months) | 227/160 |
Osserman stage | |
I | 94 (24.3%) |
IIA | 126(32.6%) |
IIB | 135 (34.9%) |
III | 11 (2.8%) |
IV | 21 (5.4%) |
Preoperative daily dose of pyridostigmine bromide (≤ 240 mg/ > 240 mg) | 309/78 |
Immunosuppressants (no/yes) | 337/50 |
Steroid (no/yes) | 337/50 |
ASA score | |
1 | 198 (51.2%) |
2 | 147 (38.0%) |
3 | 42 (10.9%) |
FEV1 | 2.6 ± 0.7 |
FEV1/FVC | 81.4 ± 8.9 |
FEV1% | 83.9 ± 18.4 |
MVV% | 80.2 ± 22.3 |
DLCO% | 90.2 ± 19.4 |
Operation time (minutes) | 128.0 ± 41.8 |
Surgical procedure (n[%]) | |
OT | 28 (7.2%) |
VAST | 359 (92.8%) |
Intraoperative blood loss (0–1000 ml/ > 1000 ml) | 383/4 |
Drainage volume over the first three days (0–800/ > 800) | 279/108 |
Ectopic thymus (yes/no) | 365/22 |
Preoperative application of gamma globulin (yes/no) | 352/35 |